IC2PerMed: a bridge between ICPerMed and China

Lili Wang, MD
王丽丽 博士
BGI genomics, China

Online workshop, November 23, 2020
Chinese strategy in PM

Key challenges and objectives:

• creation of PM sector through **China Precision Medicine Initiative (PMI)** - 15-year project to establish China as a world leader in the field
• fostering **scientific research** to understand **genetics** and **biological make-up** of people
• development of **cutting-edge data collection** and **analysis tools**
• building of powerful **high-performance computing clusters**

Fields of interest:

New clinical life sciences technologies / Large scale cohort studies /
Big Data platforms and infrastructure / Sustainable healthcare system
<table>
<thead>
<tr>
<th>Program:</th>
<th>PM National Key R&amp;D Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agency:</td>
<td>MOST, NHC</td>
</tr>
<tr>
<td>Investment:</td>
<td>64 billion RMB</td>
</tr>
<tr>
<td>Partnership:</td>
<td>Public-Private Partnerships</td>
</tr>
<tr>
<td>Participant:</td>
<td>Hospital, University, Institute, Industrial</td>
</tr>
<tr>
<td>Start:</td>
<td>2016</td>
</tr>
<tr>
<td>Duration:</td>
<td>15 years (2016-2031)</td>
</tr>
</tbody>
</table>
| Objectives: | - Promote PM interdisciplinary research and inter-sectoral collaboration through the whole value chain (data generation- translational science – healthcare system)  
- Establish and implement PM to next generation health system |
## Comparison of PM in Europe and China

<table>
<thead>
<tr>
<th>Item</th>
<th>EU</th>
<th>China</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding agency</td>
<td>ICPPerMed consortium</td>
<td>MOST (national and local)</td>
</tr>
<tr>
<td>Expert committee</td>
<td>5 challenge groups 5 action item groups</td>
<td>19 experts</td>
</tr>
<tr>
<td>Fields of interest</td>
<td>Data and technology Inter-sectoral synergies Healthcare and systems reform Education and literacy</td>
<td>New clinical life sciences technologies Large scale cohort studies Big Data platforms and infrastructure Sustainable healthcare system</td>
</tr>
<tr>
<td>vision</td>
<td>Next generation medicine</td>
<td>Health system reform</td>
</tr>
</tbody>
</table>
Big science & globalization

- 1998 • China-EU Science and Technology Cooperation Agreement
- 2009 • China-Europe Science and Technology Partnership Plan
- 2012 • Joint Statement on China-EU Innovation Cooperation Dialogue
- 2015 • China-Europe Joint Funding Mechanism for Scientific Research and Innovation
Stakeholder Group

• Full ICPPerMed membership is restricted to ministries, public and private ‘not-for-profit’ health research funding and policy organisations.

• **Stakeholder group** ICPPerMed is in close contact with all interested parties. Members of the stakeholder group are informed about ICPPerMed’s work and invited to workshops and conferences to be part of ICPPerMed. Experts and stakeholders are also invited to Executive Committee meetings for information and discussion on certain topics.
Expected impacts 1/2

**Strategic Policy Level Cooperation Impacts:**

- Create an innovative framework for European and Chinese policy stakeholders to act upon concrete steps towards the implementation of PM in their own countries.

- Ensure that the necessary regulations for the transnational deployment of PM encompass the right level of technical, social and business considerations for fostering its uptake and implementation.

- Review and discuss the scope for harmonisation of policies between EU and China for integrating PM principles in respective research collaboration schemes focusing on health.
Expected impacts 2/2

Research and Science collaboration:
• Help EU and China shape their future research collaboration frameworks for fostering scientific and technological exchanges regarding PM
• Define the areas for research, technologies and systems to achieve the structuring of an approach to improve social and healthcare systems putting PM-related ethical, equity, data security and trust at the core of future developments and assess its social impacts

EU-China PM Research, Development and Innovation ecosystems:
• Identify the key PM standards, interoperability schemes and pragmatic measures necessary for enabling joint R&D&I initiatives, notably under the ERA PerMed framework
• Confront healthcare economic principles’ realities with ethical and regulatory frameworks from both EU and China areas in the fields of PM and define best practices for implementing the adapted measures and tackle fragmentation of approaches
Bridging with China